Tuksin Jearanaiwitayakul - Search Results

Year	Number of Results
2020	1
2021	3
2022	2
2023	3
2024	1
2025	5
2026	3

1

Transcriptomic analysis of DENV-2-infected human dermal fibroblasts identified potential mechanisms that suppressed ZIKV replication during sequential coinfection.

Kaofai C, Jearanaiwitayakul T, Saisingha K, Limthongkul J, Masrinoul P, Ubol S. Kaofai C, et al. Among authors: jearanaiwitayakul t. Virol J. 2025 May 22;22(1):154. doi: 10.1186/s12985-025-02769-9. Virol J. 2025. PMID: 40399994 Free PMC article.

2

Transcriptome Analysis of Monocytes Treated With Dengue Virus Nonstructural Protein 1 Revealed a Shift in Transcripts Involved in Self-Propagated Proinflammation and Antiviral Responses.

Saisingha K, Jearanaiwitayakul T, Watterson D, Modhiran N, Ponpuak M, Ubol S. Saisingha K, et al. Among authors: jearanaiwitayakul t. J Infect Dis. 2025 Jul 11;231(6):e1170-e1182. doi: 10.1093/infdis/jiaf166. J Infect Dis. 2025. PMID: 40166903 Free PMC article.

3

Unique molecular profiling of monocyte responses to a high dose of DENV-NS1 reflected the effect of NS1 on hemostasis.

Saisingha K, Kaofai C, Modhiran N, Watterson D, Paiboonpol S, Pawaputanun A, Leaungwutiwong P, Hanboonkunupakarn B, Mansanguan C, Limthongkul J, Ponpuak M, Jearanaiwitayakul T, Ubol S. Saisingha K, et al. Among authors: jearanaiwitayakul t. Med Microbiol Immunol. 2026 May 22;215(1):17. doi: 10.1007/s00430-026-00876-0. Med Microbiol Immunol. 2026. PMID: 42171805

4

The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection.

Goldswain H, Dong X, Penrice-Randal R, Alruwaili M, Shawli GT, Prince T, Williamson MK, Raghwani J, Randle N, Jones B, Donovan-Banfield I, Salguero FJ, Tree JA, Hall Y, Hartley C, Erdmann M, Bazire J, Jearanaiwitayakul T, Semple MG, Openshaw PJM, Baillie JK; ISARIC4C Investigators; Emmett SR, Digard P, Matthews DA, Turtle L, Darby AC, Davidson AD, Carroll MW, Hiscox JA. Goldswain H, et al. Among authors: jearanaiwitayakul t. Genome Biol. 2023 Mar 13;24(1):47. doi: 10.1186/s13059-023-02881-5. Genome Biol. 2023. PMID: 36915185 Free PMC article.

5

The Adjuvant Activity of BCG Cell Wall Cytoskeleton on a Dengue Virus-2 Subunit Vaccine.

Jearanaiwitayakul T, Warit S, Lekjinda K, Seesen M, Limthongkul J, Midoeng P, Sunintaboon P, Ubol S. Jearanaiwitayakul T, et al. Vaccines (Basel). 2023 Aug 9;11(8):1344. doi: 10.3390/vaccines11081344. Vaccines (Basel). 2023. PMID: 37631912 Free PMC article.

6

A bivalent form of nanoparticle-based dengue vaccine stimulated responses that potently eliminate both DENV-2 particles and DENV-2-infected cells.

Seesen M, Jearanaiwitayakul T, Limthongkul J, Midoeng P, Sunintaboon P, Ubol S. Seesen M, et al. Among authors: jearanaiwitayakul t. Vaccine. 2023 Feb 24;41(9):1638-1648. doi: 10.1016/j.vaccine.2023.01.062. Epub 2023 Feb 3. Vaccine. 2023. PMID: 36740559 Free article.

7

Mice immunized with trimethyl chitosan nanoparticles containing DENV-2 envelope domain III elicit neutralizing antibodies with undetectable antibody-dependent enhancement activity.

Seesen M, Jearanaiwitayakul T, Limthongkul J, Sunintaboon P, Ubol S. Seesen M, et al. Among authors: jearanaiwitayakul t. J Gen Virol. 2022 Jul;103(7). doi: 10.1099/jgv.0.001768. J Gen Virol. 2022. PMID: 35833704

8

Nanodelivery system enhances the immunogenicity of dengue-2 nonstructural protein 1, DENV-2 NS1.

Jearanaiwitayakul T, Sunintaboon P, Chawengkittikul R, Limthongkul J, Midoeng P, Warit S, Ubol S. Jearanaiwitayakul T, et al. Vaccine. 2020 Oct 7;38(43):6814-6825. doi: 10.1016/j.vaccine.2020.08.021. Epub 2020 Aug 20. Vaccine. 2020. PMID: 32829977

9

A Novel Toolkit of SARS-CoV-2 Sub-Genomic Replicons for Efficient Antiviral Screening.

Erdmann M, Wing PAC, Webb I, Kavanagh Williamson M, Jearanaiwitayakul T, Sullivan E, Bazire J, Shytaj IL, McKeating JA, Matthews DA, Davidson AD. Erdmann M, et al. Among authors: jearanaiwitayakul t. Viruses. 2025 Apr 23;17(5):597. doi: 10.3390/v17050597. Viruses. 2025. PMID: 40431609 Free PMC article.

10

Intranasal immunization with the bivalent SARS-CoV-2 vaccine effectively protects mice from nasal infection and completely inhibits disease development.

Jearanaiwitayakul T, Sunintaboon P, Kittiayuwat A, Limthongkul J, Wathanaphol J, Janhirun Y, Lerdsamran H, Wiriyarat W, Ubol S. Jearanaiwitayakul T, et al. Vaccine. 2024 Jun 20;42(17):3664-3673. doi: 10.1016/j.vaccine.2024.04.079. Epub 2024 May 6. Vaccine. 2024. PMID: 38714446 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

18 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Results by year